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which index has the most prognostic power and which index is most 
useful for our daily practice? 
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Purpose/Objective: Several studies have shown that radiotherapy 
(RT) for breast cancer may be associated with an increased risk of 
heart disease. Most studies are based on patients treated before the 
era of CT-based radiotherapy, where 3D dose distributions are not 
available and dose to the heart volume needs to be estimated using 
other methods. In some previous studies a CT-scan of a representative 
patient was used to estimate heart dose, Taylor et al. (Int J Radiat 
Oncol Biol Phys2007;69:1484-95), Taylor et al. (Radiother Oncol 2009; 
90:127-35) and Taylor et al. (Radiother Oncol 2011;100:176-8). One 
limitation of this method was that inter-patient variation in heart 
dose for each technique was difficult to determine. The aim of this 
study was to estimate the variation in heart dose due to anatomical 
variation and patient movement from pre CT-based RT.  
Materials and Methods: 20 left- and 5 right-sided breast cancer 
patients treated with CT-based RT excluding the parasternal nodes 
following breast conserving surgery were selected at random from all 
women treated at our centre in 2010. The 2010 RT plan was used 
together with a reconstruction of the RT plan the patient would have 
received, if treated before the era of CT-based RT. This 
reconstruction was done according to historical guidelines using only 
external markers for field borders and machine output calculations. 
The 3D dose distributions were calculated in Pinnacle. The heart was 
contoured using a automatic method (ABAS by Elekta) with an atlas 
consisting of 15 patients. By a combination of blurring and random 
shifts of the dose, heart movement and setup uncertainty was 
simulated using a 5mm standard deviation for both the random and 
systematic error. 
Results: Mean and maximum doses to the heart are summarised in 
table 1 for the pre-CT and the 2010 CT-based RT by the median value 
and inter-quartile range (IQR). Figure 1 shows the distribution for the 
left-sided patients of mean and maximum heart doses. 
 
 
Conclusions: Non CT-planned RT does not allow precise patient-
specific sparing of organs at risk. This resulted in greater variation in 
mean heart doses in the pre CT era. The CT-planned RT included dose 
constraints to the heart and both the mean dose and the variation in 
mean dose were therefore lower. In general mean heart doses were 
low for both pre CT and CT-based RT, but the maximum doses for the 
left-sided patients showed that part of the heart received a high dose. 
The left anterior descending (LAD) coronary artery is typically located 
in this high dose region, and an increased risk of stenosis in the LAD 
following left-sided RT has indeed been reported. The approach 
applied in this study provides a method to estimate doses received by 
patients treated in the pre-CT era. Further work is needed to 
determine the doses and variations for other techniques commonly 
used in breast cancer RT, for example tangential RT including the 
parasternal lymph nodes, which is expected to result in higher heart 
doses.  
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Purpose/Objective: In the treatment of early breast cancer, axillary 
node clearance (ANC) or regional nodal irradiation following a positive 
sentinel lymph node (SLN) biopsy are therapeutic options providing 
equivalent local control. The ACOSOG Z0011 trial demonstrated 
equivalent overall survival and 5 year locoregional recurrence rates in 
patients with 1 or 2 positive SLNs offered either ANC or no further 
axillary treatment. It has been proposed that the incidental 
irradiation of lower axillary nodal levels by the whole breast 
tangential fields (TF) may explain these results. Our purpose was to 
evaluate the volume of axillary nodes encompassed within standard 
breast tangential fields, and analyse the dose delivered to each level.  
Materials and Methods: Levels 1, 2 and 3 axillary nodes were outlined 
retrospectively, using RTOG Breast Cancer Atlas Guidelines, on the 
axial CT simulation images of 50 patients who received whole breast 
irradiation alone following breast conserving surgery. Patients were 
immobilised on a breast board with both arms above their heads, and 
scanned using the local protocol. All patients received a standard dose 
and fractionation schedule with a biologically equivalent dose of 50Gy 
in 25 fractions. They were treated within ICRU 50 recommendations. 
The superior TF border was not manipulated to cover more of the 
axilla. Dose–volume histograms were used to calculate the percentage 
volume of each nodal level receiving 95% of the dose (V95%) and the 
mean dose [D mean(Gy)] at each level. 
 
 
Results: The mean dose delivered to each axillary node level was 
substantially lower than the prescribed dose. There was also a wide 
variation in the volume of levels 1 and 2 receiving 95% of the 
prescribed dose. V95% for level 3 was 0% for all patients, with a mean 
dose of only 1.8Gy. 
Conclusions: Levels 1 and 2 axillary nodes were only partially 
included in the tangential field set up. The dose delivered to all 
axillary nodal levels was lower than that considered therapeutic. 
There was a wide variation in the axillary dose coverage between 
patients. This was most likely related to multiple factors including 
patient shape and size, arm position and field borders. Certainly, our 
findings suggest that the use of standard breast radiotherapy field 
borders does not treat the axilla to a therapeutic dose and therefore 
cannot adequately explain the results seen in Z0011.  
Oncologists treating patients in the Z0011 trial may have used ‘high 
tangents’ in patients randomised to no further axillary intervention 
but these details have not yet been published. ‘High tangents’ involve 
altering the superior border of the tangential fields with the intention 
of including the lower nodal levels. Even with the use of ‘high 
tangents’, a therapeutic dose to the axilla may not be achieved. Until 
more information is available on the radiotherapy delivered within the 
Z0011 trial, we cannot assume its impact upon the results.  
 
